Biotech Values

[BTH]

Yeah, but what's another Phase 2 trial worth? 20% pop, or 50 cents or something?

They're so far off from approval of a drug right now, and, after this debacle, it's questionable if they can even properly design a trial (although, they spent tens of millions on this NSCLC trial and hopefully learned from their sloppiness). This likely trades between $1.50 (tax loss dumpage), and the higher gap ($5.00) over the next 18 months (if we're lucky). $5.00 wouldn't be bad, it's just not going to be anything of a home-run (like it would have been had they succeeded with MARQUEE ie., $15-20 stock) over the next 18 months - like I said, mainly Deadsville.